Formerly known as NanoMedex Inc, NanoMedex Pharmaceuticals Inc, is an early-stage drug improvement company founded by four University of Florida anesthesiologists, a University of Florida chemical engineer, and a business executive specializing in faculty start-ups. NanoMedex Pharmaceuticals, Inc. has developed a formulation strategy to allow drugs that are only soluble in oil to be soluble in water. To administer a drug intravenously the drug must first be dissolved in water. The NanoMedex nanotechnology formulation strategy utilizes components that encapsulate the active pharmaceutical ingredient (API) into spheres (5-30 nm) so small they allow the drug to become randomly dispersed in water and act as if the drug has dissolved in the water. NanoMedex, Inc. also worked on developing a proprietary nanotechnology designed to improve the current formulations of clinically relevant, off patent lipophilic drugs such as propofol, the most frequently used intravenous anesthetic.
